How to Start a Headache/Migraine Surgery Practice

  • David Austin BranchEmail author
  • John Beverly MooreIV
  • Ziv M. Peled


Incorporating headache/migraine operative procedures into an existing surgical practice may be challenging at first but can ultimately be very rewarding. There are several key reasons that might motivate physicians to incorporate this treatment specialty into their practice. First, some physicians are lucky enough to have trained at the rare academic center where these operative procedures are routinely taught and have seen the often life-changing results that these patients experience. For many of these physicians, there is a natural tendency to recreate their mentor’s style of practice. Other physicians may have a clinical, intellectual, or technical interest in peripheral nerve surgery from experience in hand surgery, facial nerve reconstruction, or other peripheral nerve procedures. However, the epidemiology of migraines is downright daunting. It is one of only eight disease states known to affect more than 10% of the world’s population and afflicts almost one in five Americans. Therefore, it is likely that many doctors may have friends, family, or personal experience dealing with migraines/chronic headaches and understand first-hand the immense burden these conditions place on patients and their loved ones. For these physicians, a significant motivation may be the simple desire to help ease this suffering. Moreover, some clinicians may have patients from the more than 36 million migraine sufferers in the United States who are impacted physically, socially, and occupationally by this debilitating condition and whom that have expressed to them an interest in surgical treatment for their chronic headaches. Finally, still other physicians may simply want to create a niche for their practice by offering a unique set of surgical procedures to this large and underserved patient population.


Headache surgery practice Migraine surgery practice Therapeutic botox 


  1. 1.
    Ducic I, Hartmann EC, Larson EE. Indications and outcomes for surgical treatment of patients with chronic migraine headaches caused by occipital neuralgia. Plast Reconstr Surg. 2009;123(5):1453–61.CrossRefGoogle Scholar
  2. 2.
    Guyuron B, et al. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2011;127(2):603–8.CrossRefGoogle Scholar
  3. 3.
    Burch RC, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.CrossRefGoogle Scholar
  4. 4.
    Ford JH, et al. A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 2017;57(10):1532–44.CrossRefGoogle Scholar
  5. 5.
    Lipton RB, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.CrossRefGoogle Scholar
  6. 6.
    Dodick DW, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36.CrossRefGoogle Scholar
  7. 7.
    Hu XH, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159(8):813–8.CrossRefGoogle Scholar
  8. 8.
    Rosenberg J. Migraine has impact on both healthcare costs and lost productivity. Am J Manag Care. 2018.
  9. 9.
    Stewart WF, et al. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443–54.CrossRefGoogle Scholar
  10. 10.
    Guyuron B, Tucker T, Kriegler J. Botulinum toxin A and migraine surgery. Plast Reconstr Surg. 2003;112(5 Suppl):171S–3S; discussion 174S–176S.CrossRefGoogle Scholar
  11. 11.
    Guyuron B, et al. The current means for detection of migraine headache trigger sites. Plast Reconstr Surg. 2015;136(4):860–7.CrossRefGoogle Scholar
  12. 12.
    Janis JE, Barker JC, Palettas M. Targeted peripheral nerve-directed onabotulinumtoxin a injection for effective long-term therapy for migraine headache. Plast Reconstr Surg Glob Open. 2017;5(3):e1270.CrossRefGoogle Scholar
  13. 13.
    Nahabet E, Janis JE, Guyuron B. Neurotoxins: expanding uses of neuromodulators in medicine–headache. Plast Reconstr Surg. 2015;136(5 Suppl):104S–10S.CrossRefGoogle Scholar
  14. 14.
    Liu MT, Armijo BS, Guyuron B. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg. 2012;129(2):413–9.CrossRefGoogle Scholar
  15. 15.
    Nation KM, et al. Sustained exposure to acute migraine medications combined with repeated noxious stimulation dysregulates descending pain modulatory circuits: relevance to medication overuse headache. Cephalalgia. 2019;39(5):617–25.CrossRefGoogle Scholar
  16. 16.
    Shibata Y, Ishiyama S, Matsushita A. White matter diffusion abnormalities in migraine and medication overuse headache: a 1.5-T tract-based spatial statistics study. Clin Neurol Neurosurg. 2018;174:167–73.CrossRefGoogle Scholar
  17. 17.
    ASPS policy statement: migraine headache surgery, A.S.o.P. Surgery, Editor; 2018.
  18. 18.
    Faber C, et al. A socioeconomic analysis of surgical treatment of migraine headaches. Plast Reconstr Surg. 2012;129(4):871–7.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • David Austin Branch
    • 1
    Email author
  • John Beverly MooreIV
    • 2
  • Ziv M. Peled
    • 3
  1. 1.Bangor Plastic & Hand Surgery, St. Joseph Hospital, Department of Plastic SurgeryBangorUSA
  2. 2.Department of Plastic SurgeryKansas University School of Medicine, Kansas University Medical CenterOlatheUSA
  3. 3.Peled Plastic SurgerySan FranciscoUSA

Personalised recommendations